Clinical trial · Interventional
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders
NCT00897260CI-TRIAL-00031399completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Marrow Failure Syndrome | — | UNRESOLVED | — |
| Hematological Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
- Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Primary outcomes (1)
- measure
- To determine the safety and efficacy of multiple cord blood transplantation in patients with hematological malignancy.
- timeFrame
- 1 year
Secondary outcomes (4)
- measure
- To determine the 100-day treatment related mortality (TRM), complete remission rate and the 2-year progression free and overall survival rate for patients under going this treatment.
- timeFrame
- 100 days
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Patients must have a histologically confirmed diagnosis at The Vancouver General Hospital or the BCCA-Vancouver. Eligible patients will have one of the following underlying diseases: * High risk acute lymphoblastic leukemia (ALL) in first complete remission, with high risk being defined by the presence of t(4;11), t(9;22) or t(1;19) or patients presenting with extreme hyperleukocytosis (WBC \>100x109/L) or failure to achieve a complete remission after standard induction therapy. * Acute myeloid leukemia (AML) in first complete remission with high risk cytogenetics or failure to achieve complete remission after standard induction therapy. ALL or AML in second or subsequent remission * Myelofibrosis with myeloid metaplasia. * Chronic myeloid leukemia in chronic (failed interferon and/or Gleevec) or accelerated phase. * Myelodysplastic syndrome with IPSS risk category \>Int-1 * Aplastic anemia * Non-Hodgkin's lymphoma, chronic lymphocytic leukemia or Hodgkin's disease in relapse or second or subsequent remission. * Multiple Myeloma * No active central nervous system (CNS) disease. * No 9/10 or better HLA antigen matched related donor or VUD available. * The patient's condition precludes waiting to search and find a VUD in the Unrelated Donor Registries * Acceptance of standard blood product support * Adequate organ function as defined by current Leukemia/BMT Program of BC standards (Appendix 10.1) * Karnofsky performance status ≥ 80 (Appendix 10.2) Exclusion Criteria: * Active infection * Pregnancy * Significant psychiatric disorder * Progressive disease
References
Publications (0)
Data not yet available
No reference posted for this study.